Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
MHLW Proposes NIP Inclusion of 15-Valent Pneumococcal Vaccine for Kids
The Japanese health ministry on November 9 proposed the addition of MSD’s 15-valent pneumococcal conjugate vaccine Vaxneuvance to the national immunization program (NIP) for children. Under the current NIP, a 13-valent pneumococcal conjugate vaccine (PCV13) is provided to protect children…
To read the full story
Related Article
- Pneumococcal Jabs Help Curb Pediatric Emergency Visits: Pediatrician
February 26, 2024
- Health Ministry Panel OKs Inclusion of 5-in-1 Jab in NIP from Next April
December 21, 2023
- MHLW Panel OKs Inclusion of 5-in-1 Vaccine in National Immunization Program
August 30, 2023
- MSD Files 15-Valent Pneumococcal Vaccine for Pediatric Use in Japan
August 1, 2022
REGULATORY
- MHLW Lifts Part of Approval Conditions for Takeda’s Vyvanse
June 9, 2026
- Drug Makers Seek Govt Support for Immunoglobulin Plant Investments: LDP Hearing
June 9, 2026
- Japan Govt Likely to Slim Down Honebuto, but Details Remain Elusive
June 8, 2026
- Leqembi, Kisunla Labels Revised to Strengthen ARIA Monitoring
June 8, 2026
- Japan Tightens Oversight of Mounjaro Resales: Health Minister
June 8, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…